GlassScriptPhysician profile
Remie Saab
NPI 1144803156
$2,625.75
in general payments reported to CMS, 2019-2025
22 companies · $2,515 in 2025
The $2,515 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $111 · 2025: $2,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,537 · Education: $88.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,536.76 |
| Education | $88.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $583.55 | 2025 | Tezspire, Airsupra, Fasenra |
| Amgen INC. | $288.94 | 2024-2025 | Actimmune, Tezspire, Repatha |
| Csl Behring | $271.95 | 2025 | Hizentra, Andembry, Haegarda |
| Genzyme Corporation | $207.32 | 2025 | |
| Novartis Pharmaceuticals Corporation | $153.77 | 2025 | |
| Pharming Healthcare, INC. | $141.25 | 2025 | Ruconest |
| Regeneron Healthcare Solutions, INC. | $141.07 | 2025 | Dupixent |
| Galderma Laboratories, L.P. | $114.29 | 2025 | Nemluvio |
| Genentech USA, INC. | $110.84 | 2025 | Xolair |
| Biocryst US Sales Co., LLC | $89.23 | 2025 | Orladeyo |
| Sanofi-Aventis U.S. LLC | $88.99 | 2025 | |
| Glaxosmithkline, LLC. | $78.29 | 2025 | Nucala |
| Cycle Pharmaceuticals INC | $63.04 | 2025 | Sajazir |
| Octapharma USA, INC. | $62.85 | 2025 | Panzyga, Octagam Immune Globulin (Human) |
| Takeda Pharmaceuticals U.S.A., INC. | $62.29 | 2025 | Takhzyro |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $43.10 | 2025 | |
| Leo Pharma INC. | $24.95 | 2025 | Anzupgo |
| Invivyd INC | $23.37 | 2025 | Pemgarda |
| Abbvie INC. | $22.26 | 2025 | |
| Blueprint Medicines Corporation | $21.95 | 2025 | Ayvakit |
| Tersera Therapeutics LLC | $16.75 | 2025 | Quzyttir |
| Grifols USA, LLC | $15.70 | 2025 | Gamunex-C |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Remie Saab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.